Clinical Trials Delivery Unit (CTDU) Programme Transformation Manager

Are you an experienced strategic and operational leader looking for an opportunity to shape and transform clinical research delivery within a leading neuroscience centre?

We are seeking an exceptional Programme Transformation Manager to lead the establishment and implementation of the Queen Square Clinical Trials Delivery Unit (QSCTDU). Working with the Senior Responsible Owner (SRO) and operationalising it alongside the clinical lead for the development of QSCTDU, you will provide strategic and operational leadership for an ambitious and unique programme to transform and integrate late-phase clinical trials delivery across Queen Square and wider UCLH neurosciences.

The QSCTDU will bring all late-phase clinical studies under a single operational structure, creating a more coordinated, efficient and sustainable approach to research delivery. Key priorities will include establishing a single point of access for sponsors and investigators, consolidating the research delivery workforce, streamlining study feasibility, set-up and governance, and introducing unified performance management and oversight of the research pipeline. You will also lead the development of a more integrated commercial model, supporting strategic reinvestment and future growth.

The unit will support an extensive and diverse portfolio of research across Queen Square. This presents a unique opportunity to influence and shape research delivery across a broad range of clinical disciplines.

Main duties of the job

Working with the SRO, and the clinical lead the postholder will have overall responsibility for the strategic development and operational delivery of the QSCTDU, ensuring services are delivered within agreed financial and activity parameters, to the required standards of clinical quality and in compliance with relevant clinical trials legislation and research governance requirements.

This is a significant leadership position, and you will lead complex organisational change, develop the operating model and establish the operational, financial and performance frameworks necessary to deliver a high-performing and sustainable service.

We are looking for an individual with a strong track record of leading complex research or transformational programmes, excellent financial and operational management skills, and the ability to engage and influence stakeholders across diverse clinical and professional groups.This is an exciting opportunity to play a pivotal role in shaping the future of translational research delivery at UCLH, strengthening our neuroscience research portfolio and supporting the delivery of world-class clinical research.

University College London Hospitals NHS Foundation Trust (UCLH) is one of the most complex NHS trusts in the UK, serving a large and diverse population. We provide academically led acute and specialist services, to people from the local area, from throughout the United Kingdom and overseas. Our vision is to deliver top-quality patient care, excellent education, and world-class research.

We provide first-class acute and specialist services across eight sites:o University College Hospital (incorporating the Elizabeth Garrett Anderson Wing)o National Hospital for Neurology and Neurosurgeryo Royal National ENT and Eastman Dental Hospitalso University College Hospital Grafton Way Buildingo Royal London Hospital for Integrated Medicineo University College Hospital Macmillan Cancer Centreo The Hospital for Tropical Diseaseso University College Hospital at Westmoreland Street

We are dedicated to the diagnosis and treatment of many complex illnesses. UCLH specialises in women's health and the treatment of cancer, infection, neurological, gastrointestinal and oral disease. It has world class support services including critical care, imaging, nuclear medicine and pathology.

We are committed to sustainability and have pledged to become a carbon net zero health service, embedding sustainable practice throughout UCLH. We have set an ambitious target of net zero for our direct emissions by 2031 and indirect emissions by 2040.